Celldex Therapeutics (CLDX) Return on Capital Employed Growth (1y) (2012 - 2026)
Celldex Therapeutics (CLDX) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 2,400.00 |
| 10 | Celldex Therapeutics | 2.36 Bn | 1.91 Bn | -1.44 Mn | -3,276.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,276.00 |
| Dec 31, 2025 | -2,549.00 |
| Sep 30, 2025 | -1,780.00 |
| Jun 30, 2025 | -1,318.00 |
| Mar 31, 2025 | -422.00 |
| Dec 31, 2024 | 1,982.00 |
| Sep 30, 2024 | 2,819.00 |
| Jun 30, 2024 | 1,974.00 |
| Mar 31, 2024 | 1,310.00 |
| Dec 31, 2023 | -1,155.00 |
| Sep 30, 2023 | -2,234.00 |
| Jun 30, 2023 | -1,464.00 |
| Mar 31, 2023 | -1,993.00 |
| Dec 31, 2022 | -1,731.00 |
| Sep 30, 2022 | -534.00 |
| Jun 30, 2022 | 879.00 |
| Mar 31, 2022 | 1,335.00 |
| Dec 31, 2021 | 1,101.00 |
| Sep 30, 2021 | -286.00 |
| Jun 30, 2021 | -721.00 |